CORCEPT THERAPEUTICS INC (NASDAQ:CORT) stands out as an affordable growth candidate, according to our stock screener. The company combines strong growth prospects with solid profitability and financial health, all while trading at a reasonable valuation.
Growth Prospects
CORT demonstrates impressive growth metrics:
- Revenue grew by 30.93% over the past year, with a 5-year average annual growth rate of 17.11%.
- Earnings per share (EPS) increased by 9.43% in the last year, with expectations for future EPS growth at 56% annually.
- The company’s growth trajectory is accelerating, with both revenue and earnings projected to expand faster than in previous years.
Valuation Considerations
While CORT’s P/E ratio of 58.76 appears high, it trades at a discount compared to 79.49% of its pharmaceutical industry peers. Key valuation points include:
- A forward P/E of 25.12, closer to the S&P 500 average.
- Strong free cash flow generation, with a Price/FCF ratio lower than 79.49% of industry competitors.
- Analysts expect high earnings growth, which could justify the current valuation.
Profitability & Financial Health
CORT scores well in profitability and financial stability:
- Profitability Rating: 8/10 – The company boasts a 19.55% profit margin, outperforming 93.33% of peers.
- Health Rating: 8/10 – No debt, a strong Altman-Z score (29.17), and healthy liquidity ratios highlight financial strength.
For a deeper look, review the full fundamental analysis report for CORT.
Our Affordable Growth screener lists more stocks with similar characteristics and is updated daily.
Disclaimer
This is not investing advice. Always conduct your own research before making investment decisions.
